Avaniyapuram Kannan Murugan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Avaniyapuram Kannan Murugan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Ali S. Alzahrani
Division of Molecular Endocrinology, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
8 shared publications- Ali S. Alzahrani
Department of Medicine, King Faisal Specialist Hospital and Research Centre , Riyadh 11211
4 shared publications - Arasambattu Kannan Munirajan
Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, India
3 shared publications Siddarth Kannan
School of Medicine, University of Central Lancashire, Preston PR1 2HE, UK
3 shared publicationsAli S Alzahrani
Division of Molecular Endocrinology, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211, Saudi Arabia
2 shared publications- Ebtesam Qasem
Molecular Endocrinology Section, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Center, Research Center (MBC 03), PO Box 3354, Riyadh, 11211, Saudi Arabia
2 shared publications
Latest Publications
- 28 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 320
COVID-19 vaccine-associated autoimmune thyroid eye disease: Graves’ orbitopathy
- 28 September 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 320
COVID-19 vaccine-associated autoimmune thyroid eye disease: Graves’ orbitopathy
- 14 July 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 377, 153500
Oral disease-associated proteins implicated in neuronal disorders: Emerging roles in diagnosis and treatment
- 14 July 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 377, 153500
Oral disease-associated proteins implicated in neuronal disorders: Emerging roles in diagnosis and treatment
- Open Access
- 8 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1839154
LncRNA GAS8-AS1 is downregulated, correlates with early-stage disease and lymph node metastasis, and its knockdown promotes proliferation, migration, and invasion in differentiated thyroid cancer
Background: LncRNAs emerge as critical regulators of gene expression and epigenetic modulation in human cancer. However, the biological and clinical significance of the lncRNA GAS8-AS1 in differentiated thyroid cancers (DTCs) remains poorly understood. Methods: GAS8-AS1 expression in normal tissues was evaluated using LncExpDB. Quantitative RT-PCR was performed on 21 DTCs with matched adjacent normal tissues. RNA-seq data from TCGA (507 DTCs) were analyzed to assess GAS8-AS1 expression and clinicopathological associations. Independent validation was conducted using ENCORI (510 thyroid cancer, 58 normal) and TNMplot datasets. Expression profiles of GAS8-AS1 -associated genes were analyzed in TCGA and were corroborated with ENCORI dataset. Co-expression analyses were performed to identify regulatory relationships. Functional characterization was conducted using siRNA-mediated knockdown of GAS8-AS1 in HEK293T and BCPAP cells, and overexpression studies in papillary thyroid cancer cell lines (K1 and BCPAP). Cell proliferation, migration, and invasion assays were performed. Pathway enrichment analyses were used to identify GAS8-AS1 -mediated biological processes. Results: GAS8-AS1 expression was significantly downregulated in DTCs compared with matched normal tissues ( p < 0.0001). TCGA analysis confirmed lower GAS8-AS1 expression, which was markedly associated with early-stage disease ( p = 0.03) and lymph node metastasis ( p = 0.03). GAS8-AS1 downregulation was remarkably consistent in thyroid cancer (ENCORI, p = 0.004). A dramatic downregulation of GAS8-AS1 was also observed across pan-cancer, including thyroid cancer (TNMplot, p = 2.01 × 10 -128 ). Expression analysis of GAS8-AS1 -associated genes revealed frequent deregulation in DTCs (24%), including downregulation of ATF2, ATG5, ATG7 , and BECN1 , and upregulation of NEAT1 and UCA1 . Co-expression analysis revealed that GAS8-AS1 and ATG5 expression levels were positively correlated with ATF2 , whereas NEAT1 showed a negative association, suggesting ATF2 -dependent transcriptional regulation of GAS8-AS1 , ATG5 , and NEAT1 . Functional characterizations demonstrated that GAS8-AS1 knockdown significantly increased proliferation, migration, and invasion, whereas GAS8-AS1 overexpression markedly suppressed tumor cell proliferation. Pathway enrichment analyses implicated GAS8-AS1 -related genes in autophagy, apoptosis, proliferation, invasion, and metastasis. Conclusion: These findings demonstrate that GAS8-AS1 may function as a tumor suppressor in DTCs, with its downregulation associated with disease progression and metastasis. The consistent loss of GAS8-AS1 expression and its functional impact on tumor progression suggest that it may serve as a valuable diagnostic and prognostic biomarker in DTCs.
- 8 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1839154
Open AccessLncRNA GAS8-AS1 is downregulated, correlates with early-stage disease and lymph node metastasis, and its knockdown promotes proliferation, migration, and invasion in differentiated thyroid cancer
Background: LncRNAs emerge as critical regulators of gene expression and epigenetic modulation in human cancer. However, the biological and clinical significance of the lncRNA GAS8-AS1 in differentiated thyroid cancers (DTCs) remains poorly understood. Methods: GAS8-AS1 expression in normal tissues was evaluated using LncExpDB. Quantitative RT-PCR was performed on 21 DTCs with matched adjacent normal tissues. RNA-seq data from TCGA (507 DTCs) were analyzed to assess GAS8-AS1 expression and clinicopathological associations. Independent validation was conducted using ENCORI (510 thyroid cancer, 58 normal) and TNMplot datasets. Expression profiles of GAS8-AS1 -associated genes were analyzed in TCGA and were corroborated with ENCORI dataset. Co-expression analyses were performed to identify regulatory relationships. Functional characterization was conducted using siRNA-mediated knockdown of GAS8-AS1 in HEK293T and BCPAP cells, and overexpression studies in papillary thyroid cancer cell lines (K1 and BCPAP). Cell proliferation, migration, and invasion assays were performed. Pathway enrichment analyses were used to identify GAS8-AS1 -mediated biological processes. Results: GAS8-AS1 expression was significantly downregulated in DTCs compared with matched normal tissues ( p < 0.0001). TCGA analysis confirmed lower GAS8-AS1 expression, which was markedly associated with early-stage disease ( p = 0.03) and lymph node metastasis ( p = 0.03). GAS8-AS1 downregulation was remarkably consistent in thyroid cancer (ENCORI, p = 0.004). A dramatic downregulation of GAS8-AS1 was also observed across pan-cancer, including thyroid cancer (TNMplot, p = 2.01 × 10 -128 ). Expression analysis of GAS8-AS1 -associated genes revealed frequent deregulation in DTCs (24%), including downregulation of ATF2, ATG5, ATG7 , and BECN1 , and upregulation of NEAT1 and UCA1 . Co-expression analysis revealed that GAS8-AS1 and ATG5 expression levels were positively correlated with ATF2 , whereas NEAT1 showed a negative association, suggesting ATF2 -dependent transcriptional regulation of GAS8-AS1 , ATG5 , and NEAT1 . Functional characterizations demonstrated that GAS8-AS1 knockdown significantly increased proliferation, migration, and invasion, whereas GAS8-AS1 overexpression markedly suppressed tumor cell proliferation. Pathway enrichment analyses implicated GAS8-AS1 -related genes in autophagy, apoptosis, proliferation, invasion, and metastasis. Conclusion: These findings demonstrate that GAS8-AS1 may function as a tumor suppressor in DTCs, with its downregulation associated with disease progression and metastasis. The consistent loss of GAS8-AS1 expression and its functional impact on tumor progression suggest that it may serve as a valuable diagnostic and prognostic biomarker in DTCs.
- Open Access
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1699210
COVID-19 vaccine-induced autoimmune hyperthyroidism: Graves’ disease
Graves’ disease (GD) is an autoimmune disorder that results in hyperthyroidism, in which the immune system mistakenly targets the thyroid gland, causing it to produce excessive amounts of thyroid hormones. Genetic predisposition, environmental factors such as infections and stress, disruptions in the gut microbiome, excessive iodine intake, and epigenetic changes have all been implicated in the development of GD. The recent pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed a serious global health crisis. The emergence of COVID-19 vaccines has been pivotal in combating the viral infection and its spread. However, reports of rare adverse events, including the development of autoimmune disorders such as GD following vaccination, have raised concerns. Autoimmune factors play a critical role in the pathogenesis of GD, particularly through the production of autoantibodies targeting the thyroid gland. In this review, reported cases are critically analyzed to elucidate commonalities and potential triggers for the development of this autoimmune disorder, highlighting the vital role of autoimmune mechanisms in inducing GD. We also discuss the molecular mechanisms underlying vaccine-induced autoimmunity, including antigen presentation, bystander activation, molecular mimicry, and the induction of inflammatory factors following vaccination. Understanding these mechanisms in COVID-19 vaccine-induced GD could enhance patient care and guide vaccination policies.
- 3 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1699210
Open AccessCOVID-19 vaccine-induced autoimmune hyperthyroidism: Graves’ disease
Graves’ disease (GD) is an autoimmune disorder that results in hyperthyroidism, in which the immune system mistakenly targets the thyroid gland, causing it to produce excessive amounts of thyroid hormones. Genetic predisposition, environmental factors such as infections and stress, disruptions in the gut microbiome, excessive iodine intake, and epigenetic changes have all been implicated in the development of GD. The recent pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) posed a serious global health crisis. The emergence of COVID-19 vaccines has been pivotal in combating the viral infection and its spread. However, reports of rare adverse events, including the development of autoimmune disorders such as GD following vaccination, have raised concerns. Autoimmune factors play a critical role in the pathogenesis of GD, particularly through the production of autoantibodies targeting the thyroid gland. In this review, reported cases are critically analyzed to elucidate commonalities and potential triggers for the development of this autoimmune disorder, highlighting the vital role of autoimmune mechanisms in inducing GD. We also discuss the molecular mechanisms underlying vaccine-induced autoimmunity, including antigen presentation, bystander activation, molecular mimicry, and the induction of inflammatory factors following vaccination. Understanding these mechanisms in COVID-19 vaccine-induced GD could enhance patient care and guide vaccination policies.
- 25 January 2025
- Published by Elsevier in Current Problems in Cancer
- Vol. 55, 101182
Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas
- 25 January 2025
- Published by Elsevier in Current Problems in Cancer
- Vol. 55, 101182
Immune checkpoint expression and therapeutic implications in IDH1-mutant and wild-type glioblastomas
- 13 December 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (1) , 189243
TERT promoter mutations in gliomas: Molecular roles in tumorigenesis, metastasis, diagnosis, prognosis, therapeutic targeting, and drug resistance
- 13 December 2024
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1880 (1) , 189243
TERT promoter mutations in gliomas: Molecular roles in tumorigenesis, metastasis, diagnosis, prognosis, therapeutic targeting, and drug resistance
- 5 April 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (3) , 1-11
LncRNA GAS8-AS1 dinucleotide genetic variantn.713A>G, n.714T>C is associated with early-stage disease, lymph node, and distant metastasis in differentiated thyroid cancer
Purpose Long noncoding RNAs (lncRNAs) play an essential role in the epigenetic regulation of various key genes involved in vital cellular functions. A somatic dinucleotide mutation in the lncRNA GAS8-AS1 was reported in Chinese papillary thyroid cancer. However, GAS8-AS1 dinucleotide alteration and its impact have never been explored in differentiated thyroid cancers and other populations. Methods We extracted genomic DNA from 265 DTCs and 97 normal healthy subjects, PCR amplified and Sanger sequenced to examine the GAS8-AS1 dinucleotide alteration. Calculated genotype/allele frequency to test Hardy-Weinberg Equilibrium (HWE) and performed a genetic model of inheritance to determine its association with DTC risk. Correlated the GAS8-AS1 dinucleotide variant distribution with clinical characteristics to find the association. Predicted GAS8-AS1 RNA secondary structure for wild type and variant using RemuRNA and RNAfold to assess the conformational changes. Results GAS8-AS1 dinucleotide alteration (n.713A > G, rs55742939; n.714T > C, rs61118444) identified in DTCs is a germline variant not somatic. The GAS8-AS1 genotype and allele frequency significantly deviated for HWE in DTCs (χ2 = 37.954; p = 0.0001) though not associated with its risk. Dinucleotide variant distribution was remarkably associated with early-stage disease (p = 0.002), lymph node (p = 0.01), and distant metastasis (p = 0.01) in DTCs. The GAS8-AS1 bearing dinucleotide variant markedly showed conformational change compared to that of its wild type. Conclusions These findings indicate that GAS8-AS1 is genetically deregulated and implicated in several stages of DTC tumorigenesis suggesting it could be a promising prognostic biomarker in DTCs.
- 5 April 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (3) , 1-11
LncRNA GAS8-AS1 dinucleotide genetic variantn.713A>G, n.714T>C is associated with early-stage disease, lymph node, and distant metastasis in differentiated thyroid cancer
Purpose Long noncoding RNAs (lncRNAs) play an essential role in the epigenetic regulation of various key genes involved in vital cellular functions. A somatic dinucleotide mutation in the lncRNA GAS8-AS1 was reported in Chinese papillary thyroid cancer. However, GAS8-AS1 dinucleotide alteration and its impact have never been explored in differentiated thyroid cancers and other populations. Methods We extracted genomic DNA from 265 DTCs and 97 normal healthy subjects, PCR amplified and Sanger sequenced to examine the GAS8-AS1 dinucleotide alteration. Calculated genotype/allele frequency to test Hardy-Weinberg Equilibrium (HWE) and performed a genetic model of inheritance to determine its association with DTC risk. Correlated the GAS8-AS1 dinucleotide variant distribution with clinical characteristics to find the association. Predicted GAS8-AS1 RNA secondary structure for wild type and variant using RemuRNA and RNAfold to assess the conformational changes. Results GAS8-AS1 dinucleotide alteration (n.713A > G, rs55742939; n.714T > C, rs61118444) identified in DTCs is a germline variant not somatic. The GAS8-AS1 genotype and allele frequency significantly deviated for HWE in DTCs (χ2 = 37.954; p = 0.0001) though not associated with its risk. Dinucleotide variant distribution was remarkably associated with early-stage disease (p = 0.002), lymph node (p = 0.01), and distant metastasis (p = 0.01) in DTCs. The GAS8-AS1 bearing dinucleotide variant markedly showed conformational change compared to that of its wild type. Conclusions These findings indicate that GAS8-AS1 is genetically deregulated and implicated in several stages of DTC tumorigenesis suggesting it could be a promising prognostic biomarker in DTCs.
- 16 June 2023
- Published by Springer Nature in Endocrine
- Vol. 81 (3) , 391-408
Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection affects several important organs including endocrine glands. Experimental studies demonstrated that the virus exploits the ACE2, a transmembrane glycoprotein on the cell surface as a receptor for cellular entry. This entry process is exclusively facilitated by other intracellular protein molecules such as TMPRSS2, furin, NRP1, and NRP2. Recent findings documented the involvement of the SARS-CoV-2 in inducing various parathyroid disorders including hypoparathyroidism and hypocalcemia, which received significant attention. This review extensively describes rapidly evolving knowledge on the potential part of SARS-CoV-2 in emerging various parathyroid disorders due to SARS-CoV-2 infection particularly parathyroid malfunction in COVID-19 cases, and post-COVID-19 conditions. Further, it presents the expression level of various molecules such as ACE2, TMPRSS2, furin, NRP1, and NRP2 in the parathyroid cells that facilitate the SARS-CoV-2 entry into the cell, and discusses the possible mechanism of parathyroid gland infection. Besides, it explores parathyroid malfunction in COVID-19 vaccine-administered cases. It also explains the possible long-COVID-19 effect on parathyroid and post-COVID-19 management of parathyroid. A complete understanding of the mechanisms of SARS-CoV-2-triggered pathogenesis in parathyroid dysfunctions may curtail treatment options and aid in the management of SARS-CoV-2-infected cases.
- 16 June 2023
- Published by Springer Nature in Endocrine
- Vol. 81 (3) , 391-408
Potential impacts of SARS-CoV-2 on parathyroid: current advances and trends
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection affects several important organs including endocrine glands. Experimental studies demonstrated that the virus exploits the ACE2, a transmembrane glycoprotein on the cell surface as a receptor for cellular entry. This entry process is exclusively facilitated by other intracellular protein molecules such as TMPRSS2, furin, NRP1, and NRP2. Recent findings documented the involvement of the SARS-CoV-2 in inducing various parathyroid disorders including hypoparathyroidism and hypocalcemia, which received significant attention. This review extensively describes rapidly evolving knowledge on the potential part of SARS-CoV-2 in emerging various parathyroid disorders due to SARS-CoV-2 infection particularly parathyroid malfunction in COVID-19 cases, and post-COVID-19 conditions. Further, it presents the expression level of various molecules such as ACE2, TMPRSS2, furin, NRP1, and NRP2 in the parathyroid cells that facilitate the SARS-CoV-2 entry into the cell, and discusses the possible mechanism of parathyroid gland infection. Besides, it explores parathyroid malfunction in COVID-19 vaccine-administered cases. It also explains the possible long-COVID-19 effect on parathyroid and post-COVID-19 management of parathyroid. A complete understanding of the mechanisms of SARS-CoV-2-triggered pathogenesis in parathyroid dysfunctions may curtail treatment options and aid in the management of SARS-CoV-2-infected cases.
- 13 May 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 201, 115090
Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options
- 13 May 2022
- Published by Elsevier in Biochemical Pharmacology
- Vol. 201, 115090
Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options
- 8 May 2022
- Published by Elsevier in Cancer Genetics
- Vol. 264-265, 100-108
High incidence of PI3K pathway gene mutations in South Indian cervical cancers
- 8 May 2022
- Published by Elsevier in Cancer Genetics
- Vol. 264-265, 100-108
High incidence of PI3K pathway gene mutations in South Indian cervical cancers